novo nordisk glp 1 drug Novo's Wegovy becomes first GLP-1 approved for MASH Novo's patent expires in India:

4.1 Glycaemic control outcomes Meta-analyses indicate that once-weekly GLP-1 receptor agonists provide more HbA1c reduction than twice-daily exenatide, with effectiveness similar to that of daily liraglutide (Xue et al

Mentions of Tirzepatide for blood sugar control refer to Mounjaro

Key priorities include replication in additional preclinical systems (including patient-derived oligodendrocytes), identification of molecules with reliable CNS penetration, and incorporation of biomarkers sensitive to synuclein burden and glial dysfunction

16 Fortunately, considering that these issues are easily avoided, PCOS patients generally tolerate incretin mimetics, knowing the ultimate goal is to have intact pregnancies

PVH, paraventricular hypothalamic nucleus